论文部分内容阅读
抗癌剂抗癌效果的最大障碍,是正常细胞和肿瘤细胞无明显生物学差异,因而抗癌剂有不同程度的细胞毒性,治疗指数都很低。为此,期待能开发只对肿瘤细胞具有选择性作用的抗癌剂,然而在成千上万的物质筛选中,新抗癌活性物质发现率不到1/20万。因此,以现有抗癌药尽量集中于癌巢的疗法近年来特别令人关注。这种疗法首要的是必须将药物长期限制于病灶。药物向间质渗透并穿过癌细胞膜,作用于胞浆内高分子而发挥抗癌效果。一、微胶囊抗癌剂用微胶囊,以乙基纤维素包被,平均粒径224μm。为生理盐水混悬液,可用用于血管造影的导管或18G 注射针注射。微胶囊内的水溶性抗癌剂可透过乙基纤维素半透膜缓慢释放。加工或修饰囊膜厚度
The biggest obstacle to the anti-cancer effect of anticancer agents is that there is no obvious biological difference between normal cells and tumor cells. Therefore, anticancer agents have different degrees of cytotoxicity, and the therapeutic index is very low. For this reason, it is expected to develop an anticancer agent that has a selective effect only on tumor cells. However, in the screening of thousands of substances, the discovery rate of new anticancer active substances is less than 1/200,000. Therefore, therapies that focus on cancer nests with existing anticancer drugs are of particular interest in recent years. The primary point of this therapy is that it must be limited to the lesion for a long time. The drug penetrates into the mesenchyme and passes through the cancer cell membrane, acting on intracytoplasmic macromolecules to exert an anti-cancer effect. 1. Microcapsules The microcapsules for anticancer agents are coated with ethyl cellulose and have an average particle size of 224 μm. For saline suspension, catheters for angiography or 18G injection needles can be used. The water-soluble anticancer agent in the microcapsules can be slowly released through the ethylcellulose semipermeable membrane. Processing or modified capsule thickness